Literature DB >> 2178327

Transformation renders MDR cells more sensitive to polyunsaturated fatty acids.

S Sircar1, F Cai, M E Begin, J M Weber.   

Abstract

A series of genetically related cell lines that express mdr genes but differ in their ability to form tumors has been challenged with gamma-linolenate and eicosapentaenoate to verify if the sensitivity of tumorigenic mdr cells to cytotoxic PUFAs differs from the sensitivity of non-tumorigenic mdr cells. The tumorigenic mdr cell lines were derived by transformation of their parental non-tumorigenic mdr cell line with myc and ras oncogenes. Four ras and five myc transformed cell lines were used for the estimation of clonal variability. The data as based on colony forming assays, showed that six out of nine of the tumorigenic mdr cell lines were more sensitive than the non-tumorigenic mdr cells. These results suggest that a tumorigenic phenotype renders mdr cells more sensitive to PUFAs and that PUFA supplementation either alone or in conjunction with existing forms of cancer therapy may have significant clinical implications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2178327

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Levels of thiobarbituric acid reactive substances and the cytocidal potential of gammalinolenic and docosahexaenoic acids on ZR-75-1 and CV-1 cells.

Authors:  M E Bégin; G Ells
Journal:  Lipids       Date:  1992-02       Impact factor: 1.880

2.  Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin.

Authors:  J A Plumb; W Luo; D J Kerr
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

3.  Cytotoxicity of unsaturated fatty acids in fresh human tumor explants: concentration thresholds and implications for clinical efficacy.

Authors:  David E Scheim
Journal:  Lipids Health Dis       Date:  2009-12-15       Impact factor: 3.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.